As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.
Precision Medicine Group acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.
Urovant’s Irritable Bowel Drug Fails in Phase II; Genmab Abandons Cancer Drug
Abdominal Pain, Antibody-Drug Conjugates (ADCs), Biomarkers, Business, Cancer, Clinical Trials, Irritable Bowel Syndrome with Diarrhea (IBS-D), Monoclonal Antibodies, Product Pipelines, R&D, Shares, Small Molecules, Solid Tumors, Topline DataUrovant Sciences and Genmab reported disappointing clinical trial announcements.
Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.
Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict the eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample.
Beckman Coulter will be using a grant from BARDA (the Biomedical Advanced Research and Development Authority, a division of the Dept. of Health and Human Services) to validate the ability of the company’s Monocyte Distribution Width (MDW) hematology biomarker to aid in the rapid detection of a rare but serious complication of Covid-19 affecting children.
Research Roundup: Two Types of Parkinson’s Disease and More
Adults, Aging, Biomarkers, Boston University, Brain, Cell Stem Cell, Children, Denmark, Duke University, Epigenetic, Eye Health, Human beings, Inflammatory Proteins, Lung Inflammation, Lupus, Nerve Cells, Neurodegeneration, Parkinson’s disease, Primates, R&D, Research, Science Translational Medicine, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), UniversitiesResearchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
Progentec Diagnostics Inc. launched a novel blood test to determine the likelihood that a patient with systemic lupus erythematosus (commonly known as both SLE and lupus) will experience an immunologic disease flare during the coming 12 weeks.
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More
Advanced Melanoma, Advanced Squamous Carcinoma of the Anal Canal (SCAC), Biomarkers, Blockbusters, Clinical Data, Clinical Trials, Epstein-Barr Virus, European Society for Medical Oncology (ESMO), Lung Cancer, Ovarian Cancer, PD-1/PD-L1 inhibitors, Platinum-Based Chemotherapy, R&D, TherapeuticsAstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.